OMEROS CORP (OMER) competitors & alternatives
Health Care · NASDAQ
OMEROS CORP (OMER)'s top competitors and alternatives — its most similar public companies — include Regeneron Pharmaceuticals (REGN), NOVARTIS AG (NVS), SPRUCE BIOSCIENCES INC (SPRB), Insmed (INSM), HARMONY BIOSCIENCES HLDG INC (HRMY), SAVARA INC (SVRA), Jazz Pharmaceuticals (JAZZ), Ultragenyx (RARE), TRAVERE THERAPEUTICS INC (TVTX), SOLID BIOSCIENCES INC (SLDB), AN2 THERAPEUTICS INC (ANTX) and AQUESTIVE THERAPEUTICS INC (AQST). These are OMEROS CORP's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top OMER competitors & alternatives
-
Regeneron PharmaceuticalsREGNHealth Care
Regeneron develops and commercializes monoclonal antibody and other biologics therapies across immunology, oncology, infectious disease, and other therapeutic…
$651.18 (as of 2026-07-22) · market cap $70.6B
-
NOVARTIS AGNVS
Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
$153.08 (as of 2026-07-22) · market cap $229.2B
-
SPRUCE BIOSCIENCES INCSPRBHealth Care
Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo…
$44.60 (as of 2026-07-22) · market cap $123M
-
InsmedINSMHealth Care
A biopharmaceutical company with approved rare respiratory therapies (ARIKAYCE for MAC lung disease, BRINSUPRI for bronchiectasis) and a pipeline in…
$106.64 (as of 2026-07-22) · market cap $23.4B
-
HARMONY BIOSCIENCES HLDG INCHRMYHealth Care
Harmony Biosciences is a neuroscience-focused biopharmaceutical company commercializing WAKIX (pitolisant), the first-in-class non-controlled H3 receptor…
$34.86 (as of 2026-07-22) · market cap $2.0B
-
SAVARA INCSVRAHealth Care
Savara is a clinical-stage biopharmaceutical company dedicated to developing innovative inhalable therapies for rare respiratory diseases.
$5.65 (as of 2026-07-22) · market cap $1.2B
-
Jazz PharmaceuticalsJAZZHealth Care
A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of…
$250.41 (as of 2026-07-22) · market cap $16.0B
-
UltragenyxRAREHealth Care
Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases.
$27.65 (as of 2026-07-22) · market cap $2.8B
-
TRAVERE THERAPEUTICS INCTVTXHealth Care
Rare kidney disease specialist with two approved FILSPARI formulations (IgAN, FSGS) and a clinical-stage enzyme therapy poised to become the first…
$56.26 (as of 2026-07-22) · market cap $5.2B
-
SOLID BIOSCIENCES INCSLDBHealth Care
A gene therapy company advancing a pipeline of treatments for rare neuromuscular and cardiac diseases including Duchenne muscular dystrophy, Friedreich's…
$8.10 (as of 2026-07-22) · market cap $808M
-
AN2 THERAPEUTICS INCANTXHealth Care
AN2 Therapeutics leverages a proprietary boron chemistry platform to develop small-molecule drugs for neglected infectious diseases, blood cancers, and other…
$4.89 (as of 2026-07-22) · market cap $176M
-
AQUESTIVE THERAPEUTICS INCAQSTHealth Care
Aquestive develops orally disintegrating film formulations for CNS disorders, acute seizures, and opioid use, leveraging proprietary sublingual and buccal film…
$3.94 (as of 2026-07-22) · market cap $496M
Not quite? Describe exactly what you want →
Peers are OMEROS CORP's closest public companies by shared sub-industry, sector and business themes. See the full profile: OMEROS CORP (OMER).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.